Cargando…

Clinical benefit and risk of elemene in cancer patients undergoing chemotherapy: a systematic review and meta-analysis

Introduction: Elemene injection and oral emulsion, known as elemene, have been utilized have been used in adjuvant therapy for cancer patients in China for more than 20 years. In order to evaluate the efficacy and potential risks of the treatments in cancer patients undergoing chemotherapy, a system...

Descripción completa

Detalles Bibliográficos
Autores principales: Pan, Yanhong, Wan, Panting, Zhang, Li, Wang, Cuirong, Wang, Yijun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10436211/
https://www.ncbi.nlm.nih.gov/pubmed/37601061
http://dx.doi.org/10.3389/fphar.2023.1185987
_version_ 1785092271819980800
author Pan, Yanhong
Wan, Panting
Zhang, Li
Wang, Cuirong
Wang, Yijun
author_facet Pan, Yanhong
Wan, Panting
Zhang, Li
Wang, Cuirong
Wang, Yijun
author_sort Pan, Yanhong
collection PubMed
description Introduction: Elemene injection and oral emulsion, known as elemene, have been utilized have been used in adjuvant therapy for cancer patients in China for more than 20 years. In order to evaluate the efficacy and potential risks of the treatments in cancer patients undergoing chemotherapy, a system review and meta-analysis were conducted. Additionally, the factors that may influence the outcomes were also explored. Methods: A comprehensive search was conducted across various databases including PubMed, Cochrane Library, Web of Science, EMBASE, CKNI, Wan Fang, and VIP databases. Meta-regression, subgroup, and sensitivity analyses were conducted to explore the heterogeneity. GRADE system and TSA were used to assess the strength of evidence and robustness of the results. Results: The pooled data showed that combination with elemene could improve the response rate (RR:1.48, 95%CI:1.38–1.60, p < 0.00001), disease control rate (RR:1.20, 95%CI:1.15–1.25, p < 0.00001), the rate of quality-of-life improvement and stability (WMD:1.31, 95% CI:1.12–1.53, p = 0.0006), immune function (CD4(+)/CD8(+): WMD:0.33, 95% CI:0.24–0.42, p < 0.00001), survival rate (1-year, RR:1.34, 95% CI:1.15–1.56, p = 0.0002; 2-year, RR:1.57, 95% CI:1.14–2.16, p = 0.006), and decrease the prevalence of most chemotherapy-induced side effects, especially leukopenia (Ⅲ-Ⅳ) (RR:0.46, 95% CI:0.35–0.61, p < 0.00001), thrombocytopenia (RR:0.86, 95% CI:0.78–0.95, p = 0.003), and hemoglobin reduction (RR:0.83, 95% CI:0.73–0.95, p = 0.007). However, the administration of elemene has been found to significantly increase the incidence of phlebitis in patients undergoing chemotherapy (RR:3.41, 95% CI:1.47–7.93, p = 0.004). Meta-regression and subgroup analyses discovered that the outcomes were rarely influenced by CR, CT, and dosage of elemene (DE) but the cycle number of elemene (CNE) and TT were the main sources of heterogeneity. Discussion: As the treatment time and the number of cycles increased, the efficacy of the elemene combination decreased across various aspects. Thus, shorter duration and fewer cycles are recommended.
format Online
Article
Text
id pubmed-10436211
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-104362112023-08-19 Clinical benefit and risk of elemene in cancer patients undergoing chemotherapy: a systematic review and meta-analysis Pan, Yanhong Wan, Panting Zhang, Li Wang, Cuirong Wang, Yijun Front Pharmacol Pharmacology Introduction: Elemene injection and oral emulsion, known as elemene, have been utilized have been used in adjuvant therapy for cancer patients in China for more than 20 years. In order to evaluate the efficacy and potential risks of the treatments in cancer patients undergoing chemotherapy, a system review and meta-analysis were conducted. Additionally, the factors that may influence the outcomes were also explored. Methods: A comprehensive search was conducted across various databases including PubMed, Cochrane Library, Web of Science, EMBASE, CKNI, Wan Fang, and VIP databases. Meta-regression, subgroup, and sensitivity analyses were conducted to explore the heterogeneity. GRADE system and TSA were used to assess the strength of evidence and robustness of the results. Results: The pooled data showed that combination with elemene could improve the response rate (RR:1.48, 95%CI:1.38–1.60, p < 0.00001), disease control rate (RR:1.20, 95%CI:1.15–1.25, p < 0.00001), the rate of quality-of-life improvement and stability (WMD:1.31, 95% CI:1.12–1.53, p = 0.0006), immune function (CD4(+)/CD8(+): WMD:0.33, 95% CI:0.24–0.42, p < 0.00001), survival rate (1-year, RR:1.34, 95% CI:1.15–1.56, p = 0.0002; 2-year, RR:1.57, 95% CI:1.14–2.16, p = 0.006), and decrease the prevalence of most chemotherapy-induced side effects, especially leukopenia (Ⅲ-Ⅳ) (RR:0.46, 95% CI:0.35–0.61, p < 0.00001), thrombocytopenia (RR:0.86, 95% CI:0.78–0.95, p = 0.003), and hemoglobin reduction (RR:0.83, 95% CI:0.73–0.95, p = 0.007). However, the administration of elemene has been found to significantly increase the incidence of phlebitis in patients undergoing chemotherapy (RR:3.41, 95% CI:1.47–7.93, p = 0.004). Meta-regression and subgroup analyses discovered that the outcomes were rarely influenced by CR, CT, and dosage of elemene (DE) but the cycle number of elemene (CNE) and TT were the main sources of heterogeneity. Discussion: As the treatment time and the number of cycles increased, the efficacy of the elemene combination decreased across various aspects. Thus, shorter duration and fewer cycles are recommended. Frontiers Media S.A. 2023-08-02 /pmc/articles/PMC10436211/ /pubmed/37601061 http://dx.doi.org/10.3389/fphar.2023.1185987 Text en Copyright © 2023 Pan, Wan, Zhang, Wang and Wang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Pan, Yanhong
Wan, Panting
Zhang, Li
Wang, Cuirong
Wang, Yijun
Clinical benefit and risk of elemene in cancer patients undergoing chemotherapy: a systematic review and meta-analysis
title Clinical benefit and risk of elemene in cancer patients undergoing chemotherapy: a systematic review and meta-analysis
title_full Clinical benefit and risk of elemene in cancer patients undergoing chemotherapy: a systematic review and meta-analysis
title_fullStr Clinical benefit and risk of elemene in cancer patients undergoing chemotherapy: a systematic review and meta-analysis
title_full_unstemmed Clinical benefit and risk of elemene in cancer patients undergoing chemotherapy: a systematic review and meta-analysis
title_short Clinical benefit and risk of elemene in cancer patients undergoing chemotherapy: a systematic review and meta-analysis
title_sort clinical benefit and risk of elemene in cancer patients undergoing chemotherapy: a systematic review and meta-analysis
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10436211/
https://www.ncbi.nlm.nih.gov/pubmed/37601061
http://dx.doi.org/10.3389/fphar.2023.1185987
work_keys_str_mv AT panyanhong clinicalbenefitandriskofelemeneincancerpatientsundergoingchemotherapyasystematicreviewandmetaanalysis
AT wanpanting clinicalbenefitandriskofelemeneincancerpatientsundergoingchemotherapyasystematicreviewandmetaanalysis
AT zhangli clinicalbenefitandriskofelemeneincancerpatientsundergoingchemotherapyasystematicreviewandmetaanalysis
AT wangcuirong clinicalbenefitandriskofelemeneincancerpatientsundergoingchemotherapyasystematicreviewandmetaanalysis
AT wangyijun clinicalbenefitandriskofelemeneincancerpatientsundergoingchemotherapyasystematicreviewandmetaanalysis